Physician profile
Christopher Drumm
NPI 1861661415
$1,575.52
in general payments reported to CMS, 2019-2025
18 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.17 · 2021: $48.21 · 2022: $104 · 2023: $251 · 2024: $526 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $554.72 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $328.56 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $108.35 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $99.62 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $98.05 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.08 | 2025 | Xifaxan |
| Exact Sciences Corporation | $58.52 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $38.72 | 2023 | Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $35.16 | 2024-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $32.27 | 2024 | Freestyle Libre 3 |
| Alkermes, INC. | $28.80 | 2024 | Vivitrol |
| Dynavax Technologies Corporation | $23.47 | 2024 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.83 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $21.53 | 2022 | |
| Axsome Therapeutics, INC. | $17.34 | 2025 | Symbravo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.86 | 2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2025 | Zoryve |
| Allergan, INC. | $12.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Drumm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.